Abstract Library
Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.
Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.
ENETS Abstract Search
#4340 Predominant volumetric phenotype in dual PET and overall survival in NENs
Introduction: Dual 18F-FDG/68Ga-DOTATATE PET can predict NEN prognosis and guide treatment choice. However, research to date (such as the NEPTET score) has focused on the dual PET phenotype of single-point lesions rather than of the total disease volume.
Conference:
Presenting Author: Chan D
Authors: Chan D, Bernard E, Mokhtar S, Chou A, Gill A,
Keywords: Prognostic biomarker, PET/CT, tumour volume, 18F-FDG, 68Ga-DOTATATE,
Introduction: Scans are integral to neuroendocrine tumor (NET) management. There are no guidelines regarding timing of scans and results communication from a patient (pt.) perspective.
Conference: 18th Annual ENETS Concerence (2021)
Presenting Author:
Authors: Gillespie J, Wakelin K, Cummins M, Golden K, Chan D,
Keywords: consumer, patient preferences, imaging, collaborative consumer research, communication, self-management, health service delivery,
Introduction: A prediction model to predict recurrence within 5 years after surgery for nonfunctional pancreatic neuroendocrine tumors (PanNets) was recently published. This model includes WHO tumor grade, lymph node status and perineural invasion as predictors.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Heidsma C, Van Dieren S, Gill A, Engelsman A, Strobel O,
Keywords: Prediction model, recurrence, pancreatic neuroendocrine,
Introduction: In NET, radiological response to chemotherapy is often delayed and the importance of interval-imaging during treatment has not been determined.
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author:
Authors: Miller R, Childs A, Gillmore R, Mayer A, Thirlwell C,
Keywords: NETs, chemotherapy, imaging,
Introduction: Patients with NET compound a specific cancer population: their survival used to be longer than other cancer patient populations and they received drugs (eg. somatostatin analogues) rarely used on others. The systematic measure of QL in these patients could lead to better understanding of the impact of the disease and treatments, not only in terms of symptom prevalence but also in relation to daily concerns.
Conference: 11th Annual ENETSConcerence (2014)
Presenting Author: PESCE V
Authors: Grance G, Pesce V, Bestanti C, O'Connor J, Roca E,
Keywords: NET, quality of life, symptom burden, supportive care,